Curium Announces Strategic Partnership with PeptiDream for Prostate Cancer Theranostics in Japan
Collaboration to include the clinical development, regulatory filing, and commercialization in Japan of 177Lu-PSMA-I&T and 64Cu-PSMA-I&T Builds on long-standing relationship between the two companies In Japan around 90,000 new cases of prostate cancer are diagnosed each year PARIS, Oct. 01, 2024 (GLOBE NEWSWIRE) — Curium, a world leader in nuclear medicine, announced today that it has entered into a strategic partnership with PDRadiopharma Inc, a wholly-owned subsidiary of PeptiDream, for the clinical development, regulatory filing, and commercialization in Japan of 177Lu-PSMA-I&T and 64Cu-PSMA-I&T. The two agents 177Lu-PSMA-I&T and 64Cu-PSMA-I&T target prostate specific membrane antigen (PSMA) expressed on prostate cancer cells and are being investigated for prostate